Caffeine therapy for apnea of prematurity

Schmidt, Barbara; Roberts, Robin S; Davis, Peter; Doyle, Lex W; Barrington, Keith J; Ohlsson, Arne; Solimano, Alfonso; Tin, Win; Pfister, Riccardo

doi:10.1056/NEJMoa054065

Scientific article

Open access

English

Caffeine therapy for apnea of prematurity

ContributorsSchmidt, Barbara; Roberts, Robin S; Davis, Peter; Doyle, Lex W; Barrington, Keith J; Ohlsson, Arne; Solimano, Alfonso; Tin, Win; Pfister, Riccardo

Published inThe New England journal of medicine, vol. 354, no. 20, p. 2112-2121

Publication date2006

Abstract

Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.

Keywords

Apnea/drug therapy/therapy
Bronchopulmonary Dysplasia/prevention & control
Caffeine/pharmacology/therapeutic use
Central Nervous System Stimulants/pharmacology/therapeutic use
Combined Modality Therapy
Female
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases/drug therapy
Infant, Very Low Birth Weight
Logistic Models
Male
Oxygen Inhalation Therapy
Respiration, Artificial
Weight Gain/drug effects

Affiliation

Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Research group

Réanimation néonatale en salle d'accouchement (696)

Citation (ISO format)

SCHMIDT, Barbara et al. Caffeine therapy for apnea of prematurity. In: The New England journal of medicine, 2006, vol. 354, n° 20, p. 2112–2121. doi: 10.1056/NEJMoa054065

Article (Published version)

Identifiers

PID : unige:46930
DOI : 10.1056/NEJMoa054065
PMID : 16707748

ISSN of the journal0028-4793

1441views

2608downloads

Creation2015/01/29 15:45:00

First validation2015/01/29 15:45:00

Update time2023/03/14 22:52:05

Status update2023/03/14 22:52:04

Last indexation2024/01/16 16:51:26

Archive ouverte UNIGE

Caffeine therapy for apnea of prematurity

Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.

Technical informations